28th Apr 2014 15:18
LONDON (Alliance News) - GlaxoSmithKline PLC said Monday that its compound Incruse had been granted marketing authorisation by the European Commission as a treatment for chronic obstructive pulmonary disease.
Glaxo expects the product to launch in Europe by the end of 2014.
Incruse is an inhalation powder, which is delivered using the Ellipta inhaler.
Glaxo's and Theravance Inc Monday launched their chronic obstructive pulmonary disease treatment Anoro Ellipta at retail pharmacies in the US.
Under the terms of its agreement with Glaxo, Theravance has agreed to make a milestone payment of USD30 million to Glaxo following the US launch of the product.
Also on Monday, Glaxo announced that in conjunction with Medicines for Malaria Venture, it will be beginning a Phase III programme to evaluate tafenoquine for the treatment and relapse prevention of Plasmodium vivax malaria.
The Phase III programme will investigate the efficacy and safety of the treatment in two double-blind treatment studies.
Shares in Glaxo were trading up 0.1% at 1,657.00 pence Monday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline